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Mutations in DAX1 [dosage-sensitive sex reversal-adrenal hy-
poplasiacongenita(AHC)criticalregionontheXchromosome
gene 1; NR0B1] cause X-linked AHC, a disease characterized
by primary adrenal failure in infancy or childhood and re-
productive abnormalities later in life. Most of these patients
have nonsense or frameshift mutations that cause premature
truncation of the DAX1 protein, thereby eliminating its tran-
scriptional silencing activity. We evaluated a patient with an
unusual form of AHC manifest as late-onset adrenal insuffi-
ciency and gonadal failure. DNA sequence analysis revealed
a novel amino-terminal DAX1 nonsense mutation (Q37X), pre-
dicted to cause a severe truncation of the protein. Using a
combinationofinvitrotranslationassaysandstudiesofDAX1
expression and function in transfected cells, we demonstrate
that, in contrast to more distal mutations leading to a non-
functional protein, this mutation is associated with a milder
phenotype due to the expression of a partially functional,
amino-truncated DAX1 protein generated from an alternate
in-frame translation start site (methionine, codon 83). The
production of this amino-truncated isoform appears to rescue
the classical AHC phenotype, thereby delaying the onset of
clinically significant adrenal dysfunction until early adult-
hood. Thus, this case demonstrates a relatively rare phenom-
enon by which the clinical severity of an inherited human
disease is reduced after alternate translation from a site
downstream of a premature stop codon. (J Clin Endocrinol
Metab 88: 417–423, 2003)
D
AX1 (also known as adrenal hypoplasia congenita
(AHC), NR0B1) encodes an orphan nuclear receptor
that regulates the development and function of the adrenal
gland and hypothalamic-pituitary gonadal axis (1, 2). The
carboxyl-terminal region of DAX1 resembles the ligand-
binding domain (LBD) of other nuclear receptors, whereas
theamino-terminusconsistsofauniquerepeatstructurethat
contains several LXXLL-like motifs implicated in protein-
protein interactions (3). Functional studies suggest that
DAX1 is a repressor of gene transcription, acting in part by
inhibiting the activity of another nuclear receptor, steroido-
genic factor-1 (SF1, NR5A1) (4).
Mutations or deletions of DAX1 cause X-linked AHC
(AHC OMIM, 300200) (1). AHC is an inherited disorder of
adrenal gland development, characterized by lack of the
permanent zone of the adrenal cortex. Boys with this con-
dition usually present with severe primary adrenal failure in
infancy or childhood. Hypogonadotropic hypogonadism be-
comes apparent at puberty, and infertility results from go-
nadotropin deficiency in combination with a primary defect
in spermatogenesis (5, 6). Over 80 different mutations in
DAX1 have been described (7), most of which are nonsense
or frameshift mutations that cause premature truncation of
the protein. Deletion of as few as the last nine amino acids of
DAX1, which constitute a putative activation function-2 (AF2)
domain, is associated with a severe clinical phenotype (8).
Recently, an adult-onset form of AHC has been described
in two patients who have missense mutations in the putative
LBD of DAX1 (9, 10). These mutations (I439S, Y380D) were
shown to have intermediate levels of repressor activity in
transient gene expression studies, consistent with the mild
phenotype of the affected individuals. Other variant pheno-
types include isolated hypogonadotropic hypogonadism in
a female homozygous for a DAX1 mutation through gene
conversion and extreme pubertal delay in heterozygous fe-
male carriers (6, 11). Here we report a novel mechanism of
mild AHC; namely, reduced production of a shorter DAX1
isoform resulting from alternate translation downstream to
an amino-terminal stop codon. Our observations provide a
rareexampleofthephenotypicrescueofaninheriteddisease
by the circumvention of an otherwise severe mutation at the
level of translation.
Materials and Methods
DNA sequencing and mutational analysis
After obtaining written consent, genomic DNA was extracted from
peripheral blood leukocytes using standard procedures. Both exons of
DAX1 were amplified by PCR using specific oligonucleotide primer
pairs and conditions described previously (12). Direct sequencing of
PCR products was performed using a Taq Big Dye Terminator Sequenc-
ing Kit and ABI 3100 automated sequencer (PE Applied Biosystems,
Foster City, CA).
Abbreviations: AF2, Activation function-2; AHC, adrenal hypoplasia
congenita; LBD, ligand-binding domain; SF1, steroidogenic factor-1;
WT, wild type.
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417Construction of human DAX1 expression vectors
DAX1expressionvectors(pCMX)containingtheQ37X,W39X,F448X,
M83K, and Q37X/M83K mutations were created by overlapping PCR
using methods described previously (9, 13). Expression vectors contain-
ing cDNA for wild-type (WT) DAX1, the naturally occurring Y399X
nonsense mutant (13), and an artificial F448X mutant were used as
positive and negative controls for both DAX1 function and in vitro
translation.
The construction of the amino-terminally deleted expression vectors
lacking the first 40, 80, and 85 amino acids was made by insertion of the
PCR-generatedfragments(seebelow)afterdigestionwithEcoRIandSplI
(d40), and EcoRI and BspEI (d80, d85), respectively.
The following primer pairs were used to amplify the three fragments,
respectively: 1) forward, 5-GATCGAATTCTGTTCGTGCGGCGAT-
GAG-3; and reverse, 5-CCTCTGCGCGAAG TAGGAGC-3;2 )
forward, 5-GATCGAATTCTACAGCATGCTGACG AGCG-3; and re-
verse, 5-G GACGCCCAGCAGTTGCGCA-3; and 3) forward, 5-G
ATCGAATTCAGCGCAAAGCAAACG TAC-3; and reverse, 5-GGA
CGCCCAGCAGTTGCGCA-3.
To allow antibody-mediated detection of recombinant DAX1 pro-
teins, DAX1 cDNAs for WT and Q37X were cloned into the pcDNA
6/V5-HisA expression vector (Invitrogen, Carlsbad, CA). Briefly,
cDNAswereamplifiedusingprimersthatintroduceNheIandEcoRIsites
(forward, 5-GATCGCTAGCCAGTGGGCAGAAC TGGGCTAC-3; re-
verse, 5-GATCGAATTCTATC TTTGTACAGAGCATTTC-3), and
PCR-generated fragments were cloned into the expression vector after
digestion with the corresponding endonucleases.
The presence of the desired mutations/deletions and the integrity of
the constructs were confirmed by direct sequencing before studies of
protein expression and function.
In vitro translation of WT and mutant DAX1
WTandmutantDAX1cDNAswereinvitrotranscribedandtranslated
in the presence of [
35S]methionine using a TNT-coupled reticulocyte
lysate system (Promega Corp., Madison, WI). A total of 250 ng of each
dsDNA template were incubated at 30 C for 90 min in a reaction mixture
of 12.5 l. Denatured protein products were resolved with SDS-PAGE
and detected by autoradiography after overnight exposure.
Western blotting
Human embryonic kidney tsa201 cells were transfected with 10 g
pcDNA6/V5-HisA DAX1 WT or Q37X. Equivalent amounts of protein
lysates from transfections were resolved with SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes using standard meth-
ods. Blots were blocked in Tris-buffered saline containing 0.1% Tween
20 and 5% skim milk powder; incubations with antibodies were per-
formed in the same buffer but without the skim milk powder. Recom-
binantDAX1wasprobedwitha1:5,000dilutionoftheprimaryantibody
toward the V5 epitope and a 1:10,000 dilution of the secondary anti-
mouse antibody. Reactive bands were detected using a chemilumines-
cencekit(NENLifeScienceProducts,Boston,MA)withKodakMSx-ray
film (Rochester, NY).
Functional analysis of WT and mutant DAX1
Transient gene expression studies were performed using human em-
bryonic kidney tsa201 cells grown in DMEM supplemented with 10%
fetal bovine serum and 1% streptomycin/penicillin in a 5% CO2 atmo-
sphere at 37 C. A luciferase reporter construct (500 ng) containing the
nativeratLHpromoter(154to5)wascotransfectedwithexpression
vectors containing full-length human SF1 (NR5A1; 20 ng), full-length rat
early growth response-1 (Egr1; 20 ng), and full-length human WT or
mutantDAX1(50ng),asdescribedpreviously(10,14).Luciferaseassays
were performed 48 h later. The results of triplicate transfections are
expressed as the mean  sem.
Quantitation of DAX1 mRNA
DAX1 mRNA levels were measured by RT-PCR using real-time flu-
orescent detection. Enzymes were purchased fromPE Applied Biosys-
FIG. 1. Photomicrograph (hematoxylin and eosin staining; magnification, 50) of the testicular biopsy. Disorganization of the normal tubular
structure and abnormal proliferation of the interstitial tissue. Inset, moderate Leydig cell hyperplasia (magnification, 200). Ectasia of the rete
testis was also noted by Doppler ultrasound (data not shown).
418 J Clin Endocrinol Metab, January 2003, 88(1):417–423 Ozisik et al. • Alternate DAX1 Translation in Mild X-Linked AHCtems, and assays were carried out according to the manufacturer’s
protocol. Detection was performed on an ABI 7700 sequence detector.
Sequences were: 5 primer, CTGCAGCACCATTTGGCAC; 3 primer,
GGT ACTGATGTTCAGACTCCAGCAT; probe, FAM-CCTCCCAG-
GTCCAAGCCATCAAGTG-BlackHoleQuench (Quiagen Operon, Ala-
meda, CA). To permit quantitation of copy number, a 259-bp fragment
encompassing the RT-PCR amplicon was subcloned into the pGEM-3z
plasmid and transcribed using T7 RNA polymerase. A linear dilution of
the transcribed RNA was included in each assay as a standard curve.
Results
Clinical presentation of late-onset AHC
A 20-yr-old male presented with a history of fatigue, nau-
sea, and hyperpigmentation. Clinical laboratory investiga-
tions revealed hypocortisolemia (25 nmol/liter; normal
range, 140–700), hypoaldosteronism, and elevated ACTH
(226pg/ml;normal,10–60),consistentwithprimaryadrenal
failure.Hewashypogonadal(4-mltestesbilaterally)andhad
subnormal testosterone (7.5 nmol/liter; normal, 10–35), nor-
mal LH (4.8 IU/liter; normal, 1–5), and elevated FSH (20
IU/liter; normal, 1–5) with low inhibin B levels (43.5 pg/ml;
normal,100–400).TheSertolicellaromatasebioassay,which
evaluatestheFSH-dependentaromataseactivity(conversion
of androgen substrate to estradiol) in cultured Sertoli cells
from 7- to 10-d-old rats, revealed a normal bioactive/immu-
noreactive ratio (0.49; normal, 0.3–1.5), indicating the pres-
ence of biologically active FSH in the patient’s serum.
Azoospermia was found on semen analysis and did not
improve after 6 months of treatment with exogenous gonad-
otropins. Testicular biopsy revealed disorganization of the
normal seminiferous tubular structure, and there was mod-
erate Leydig cell hyperplasia (Fig. 1), confirming an intrinsic
defect in spermatogenesis similar to that found in Ahch (also
known as Dax1) knockout mice (15, 16). There was no family
history of affected males. The patient’s mother was not avail-
able for genetic testing.
Diagnosis of X-linked AHC and characterization of the
molecular mechanism leading to the unexpected
mild phenotype
Direct DNA sequencing revealed a novel nonsense mu-
tation (Q37X, CAG3TAG) in the amino-terminal region of
DAX1 (Fig. 2A), which is predicted to result in a severely
truncated protein devoid of repressor activity. However,
consistent with the mild clinical phenotype, transient gene
expression studies unexpectedly showed that this mutation
causes only partial loss of DAX1 function (Fig. 2B). Similar
results were obtained after the introduction of a W39X mu-
tationintoDAX1,achangereportedrecentlyinapatientwith
transient neonatal hypoaldosteronism due to AHC who did
not develop significant adrenal dysfunction until adoles-
cence (17).
We hypothesized that the mild clinical phenotype seen in
patients with these amino-terminal nonsense mutations
might be accounted for by alternate translation from a site
downstream of the mutation, yielding an amino-truncated,
yet partially functional, form of the protein. Compared with
WT DAX1 (51-kDa), in vitro proteins translated from cDNA
constructs containing the Q37X or W39X mutations gener-
ated a shorter protein product of 43 kDa (Fig. 1B). This
43-kDa band is also faintly visible in the WT lane, suggesting
that this protein may be normally expressed as a minor
protein variant.
The translation of this smaller protein product in the pres-
ence of the Q37X mutation was confirmed by Western blot
analysis (Fig. 3A). Levels of mutant protein were lower than
WT levels in the experiments. This observation appears to
FIG. 2. A, Schematic representation of the human DAX1 (NR0B1)
gene. The amino-terminal repeat motif is shown. The LxxLL-type
domains are indicated by gray boxes and begin at amino acids 13
(LYNML), 80 (LYSML), and 146 (LYSLL). The position of the Q37X
nonsense mutation described in this report is also shown along with
those of W39X, Y399X (another naturally occurring mutation that is
associated with a severe AHC phenotype), and an artificial F448X
mutant that removes the putative AF2 domain. B, Transcriptional
activity of mutant DAX1. A luciferase reporter construct (500 ng)
containing the native rat LH promoter (154 to 5) was cotrans-
fected into tsa201 cells with expression vectors containing full-length
human SF1 (NR5A1; 20 ng), full-length rat early growth response-1
(Egr1) (20 ng), and full-length human WT or mutant DAX1 (50 ng).
Both Q37X and W39X mutants showed only partial loss of DAX1
wild-type repressor function compared with the more profound loss of
repressionactivityseenwiththeC-terminaldeletionmutants(Y399X
and F448X). Data are presented as a percentage (SEM) of empty
vector activity (100%) for triplicate experiments. Partial loss of re-
pressor function was similarly observed with both native rat aro-
matase (Cyp19) and inhibin  promoters (data not shown). WT and
mutant DAX1 cDNAs were in vitro transcribed and translated using
a reticulocyte lysate system in the presence of [
35S]methionine. As
expected, WT DAX1 cDNA produced a 51-kDa protein. The Q37X
cDNA as well as W39X generated a shorter 43-kDa product, which
was weakly detectable in the WT lane.
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site,asmRNAlevelswerenotdifferentforthetwoconstructs
(Fig. 3B).
Examination of the DAX1 nucleotide sequence identified
a putative internal in-frame translation start site, with a par-
tially conserved Kozak consensus sequence flanking the me-
thionine at codon 83 (AGCATGC) (18). This methionine res-
idue lies within the second LXXLL-like motif in DAX1 and
is highly conserved among several species (Fig. 4A) (19).
Serial amino-terminal deletions of DAX1 were made to in-
vestigate the putative role of M83 in translation initiation. A
loss of function occurred with progressive deletion from
codon 80 to codon 85 (Fig. 4B). Further, introduction of an
M83K missense mutation (ATG3AAG) at the putative
translation start site did not affect WT DAX1 repressor ac-
tivity, but abolished synthesis of the 43-kDa product. As
expected, introduction of this M83K missense mutation into
the background of the Q37X mutant sequence impaired
DAX1 function and prevented translation of the shorter iso-
form (Fig. 4C). These findings suggest that methionine 83
serves as an alternative internal translation initiation codon.
Discussion
The presentation of X-linked AHC in an adult male is
unusual and prompted us to investigate the functional prop-
erties of the Q37X mutant. The premature termination of the
DAX1 protein at amino acid residue 37 was predicted to
generate a small peptide devoid of repressor activity. The
partially preserved repressor function of this mutant in tran-
sient gene expression studies was surprising and led us to
consider the possibility that translation might occur at an
alternate site downstream from this codon, thereby leading
to an amino-truncated, yet partially functional, protein. Sev-
eral independent lines of evidence support this idea, includ-
ing 1) the expression of shorter 43-kDa protein in an in vitro
translation assay; 2) the loss of the 43-kDa product after
deletion or introduction of a missense mutation into methi-
onine 83; 3) detection of the shorter protein in transfected
cells; and 4) the correlation of transcriptional repression with
expression of the truncated protein.
The amino-terminus of DAX1 is unusual among nuclear
receptors because it consists of a repeat domain structure
containing three LXXLL-like motifs implicated in protein-
protein interactions instead of a characteristic zinc finger
DNA-binding domain. The alternatively translated Q37X
mutant DAX1 predicted for this patient would lack 82 amino
acids at the N terminus, thereby disrupting the first two
LXXLL-like motifs. The partial loss of function observed in
this amino-terminally truncated protein and the mild phe-
notype of the patient suggest that the first 82 amino acids are
partly dispensable, and that conservation of one motif is
sufficient for residual DAX1 function.
Asnotedpreviously,the43-kDabandisalsofaintlyvisible
when the WT protein is translated, suggesting that the ri-
bosomes can bypass the optimal M1 site and initiate trans-
lation at the downstream M83 site. However, these in vitro
experiments do not allow us to determine whether transla-
tion initiation at this position occurs at low levels in normal
subjects or whether this alternate site is preferentially used
in the presence of an upstream premature stop codon.
The levels of the alternately translated Q37X and W39X
isoforms are less than that of the WT protein. There are at
least three possible mechanisms for this: 1) although Kozak
sequence flanking the ATG at position 83 suggests that it can
be used as an initiator methionine (18), translation from
internal methionines may be less efficient; 2) eukaryotic cells
employ proofreading systems to identify and degrade
mRNAs that harbor a premature stop codon or lack a ter-
mination codon (i.e. nonsense-mediated mRNA decay and
nonstop mRNA decay, respectively) (20, 21). We did not
observe such a decrease in transcript levels in transiently
transfected cells, but interpret this finding with caution be-
cause mRNA stability may differ in vivo; or 3) the truncated
DAX1 protein itself may be unstable.
In humans, milder phenotypes of inherited disorders can
arise by various mechanisms. For example, exon skipping
hasbeenreportedasamechanismtorestoreanopenreading
frame in cases in which an mRNA transcript otherwise con-
tains nonsense or frameshift mutations [Becker muscular
dystrophy(OMIM310200),etc.](22–24).Recently,alternative
translation using an open reading frame generated by a 5-bp
deletion in NBS1 has been suggested to produce a protein
that diminishes the severity of the Nijmegen breakage syn-
drome (OMIM 602667) phenotype in humans (25). This find-
ing provides an explanation for why Nbs1-null mice are not
viable, but humans who are homozygous for the 657del5
allele survive, albeit with a predisposition to develop cancer
later in life. Of note, an unexpectedly mild (and late-onset)
FIG. 3. A, Detection of the recombinant
DAX1 proteins containing the carboxyl-
terminal V5 epitope and a polyhistidine
tag. Whole cell extracts were probed with
the anti-V5 antibody by Western blotting.
Reactive bands represent 56- and 48-kDa
products for the WT and Q37X mutants,
respectively (the epitope and the tag add
approximately 5 kDa to the molecular
massofthecorrespondingproteins).B,WT
and Q37X transcript levels measured after
2, 4, 8, and 24 h of transfection. The bars
represent the copy number of mRNA de-
tected by real-time fluorescent RT-PCR
(the results of triplicate transfections are
expressed as the mean  SEM).
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was identified in a patient compound heterozygous for two
seemingly severe mutations in the PEX12 gene. Molecular
studies suggest that the transcript of the allele harboring a
2-bp deletion in codon 9 allows translation of a shorter pro-
tein from a downstream in-frame methionine (26). It appears
that internal ribosome entry is the mechanism underlying
this mild phenotype. Finally, although alternative protein
isoforms resulting from different translation start sites are
recognized to have different biological roles (e.g. glucocor-
ticoid and progesterone receptor A and B isoforms) (27–29),
the importance of these isoforms in human disease has yet
to be defined.
There are other rare instances where amino-terminally
truncated proteins are generated by downstream initiation
after premature termination in the extreme amino terminus.
However, in all of these cases the amino-truncated protein
does not possess sufficient function to reduce the severity of
the clinical phenotype (30–32). DAX1 is different from these
other proteins because it contains a repeat motif structure in
the amino terminus with presumed functional redundancy
among the motifs. In contrast, loss of the carboxyl terminus
of DAX1 (including the AF2 domain) produces a severe
clinical phenotype, whereas partial or less severe disease
phenotypes have been reported when a premature stop
codon leads to a carboxyl truncation of other proteins (33).
FIG. 4. A,Kozaksequencesflankingmethioninesatcodon
1 (M1) and 83 (M83); M1 displays a consensus Kozak
sequence, whereas M83 lacks a guanosine at position 4.
Conservation of the methionine within the LXXLL-like
motif among human, mouse, and pig, but not chicken and
alligator, is also shown. B, Mapping of the alternate trans-
lation start site. Three expression vectors containing dif-
ferent amino-terminal deletions were generated lacking
the first 40, 80, and 85 amino acids (d40, d80, and d85),
respectively. The two most amino-terminal deletion mu-
tants showed conserved DAX1 repressor activity in func-
tional studies, whereas d85, which lacks the predicted
alternative initiation site (M83), showed a complete loss of
DAX1 function. When these three amino-terminal dele-
tion mutants were in vitro translated, the 43-kDa protein
was present in those containing M83. In contrast, its
translation was abolished in the d85 mutant. C, Replace-
mentofmethionineatcodon83withlysine(M83K)didnot
affect DAX1 function, but prevented in vitro synthesis of
the shorter DAX1 protein. When both Q37X and M83K
mutations were introduced into DAX1, no bands were de-
tected by in vitro translation. In functional assays, a more
profound loss of repression was observed than in the con-
struct containing the Q37X mutation alone.
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ious proteins depend on whether deletion of the carboxyl
terminus affects domains that are important for protein sta-
bility or function. Finally, reduced translational efficiency
due to point mutations that alter the consensus context of the
authentic ATG initiator represents another mechanism un-
derlying less severe disease phenotypes (34).
The data presented here suggest that internal in-frame
translation of a shorter DAX1 protein partially rescues the
clinical phenotype of a patient with a nonsense mutation in
the extreme amino terminus of DAX1 and delays the onset
of adrenal dysfunction. Interestingly, except for the Q37X
and W39X variants, other naturally occurring nonsense or
frameshift mutations that cause a premature termination
codon 5 to the putative alternative start site (codon 83) are
associated with the classical AHC phenotype (35–37). In one
of these cases (35), it is possible that the relative proximity of
thenonsensemutation(codon81)interfereswithrecognition
of the juxtaposed alternate start site by ribosomes. Similarly,
deletion or insertion of nucleotides (36, 37) may disrupt the
sequence required for internal ribosomal entry, thereby im-
pairing alternate translation start.
Of note, all missense mutations in DAX1 reported to date
are located within the putative carboxyl-terminal LBD (13).
Functional redundancy may exist within the amino-terminal
repeat motif structure, which varies in number in different
species (19). The presence of at least one repeat in the trans-
lated protein appears to be sufficient to preserve partial
DAX1 function, particularly in view of the fact that the
amount of expressed protein is likely to be reduced.
Here, we show that translation from an internal in-frame
start site downstream of a nonsense mutation can reduce the
clinical severity of AHC. On the other hand, in the case of
DAX1, gene dosage appears to play a critical role in protein
function (38). Thus, it is possible that the clinical features
reflect reduced expression from a hypomorphic allele in ad-
dition to effects on the protein itself. Our findings also dem-
onstratethatresidualDAX1functionissufficienttodelaythe
onsetofovertadrenalfailure,butisnotcapableofsupporting
normal testis development and function.
One might predict from this observation with DAX1 that
the physiological impact of polymorphic variants or muta-
tions in other genes might also be modified when functional
protein products can be produced from alternative transla-
tion initiation sites.
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